Reversion of multidrug resistance in tumor by biocompatible nanomaterials.
In this review we have focused on the utilization of the biocompatible nanomaterials to reverse multidrug resistance (MDR), a major clinical obstacle in cancer therapeutics. Based on the comprehension of the mechanism of MDR and common reversal methods, the strategies and key properties of anti-MDR nanomaterials are explored and described to show how these features could provide the potential therapeutic effects that are not achievable with other modalities. The use of biocompatible nanoparticles with different designs and therapeutic approaches to reverse the MDR of cancer chemotherapeutics offers promising opportunities to benefit patients in the future.
Zhang
H
H
Zhongda Hospital, School of Clinic Medicine, Southeast University, Nanjing 210009, China. zhanghaijunseu@163.com
Jiang
H
H
Wang
X
X
Chen
Baoan
B
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use; D001672:Biocompatible Materials / Q000737:chemistry; D004337:Drug Carriers / Q000737:chemistry*; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D006801:Humans; D049329:Nanostructures / Q000737:chemistry*; D009369:Neoplasms / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D001672:Biocompatible Materials; D004337:Drug Carriers